



Hikma Meet the Management Day London

London, 23 October 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, will host a Meet the Management Day in London on Tuesday 2 December 2014.

The event will take place at The Westbury Hotel, 2nd Floor Westbury Gallery, Bond Street, London, W1S 2YF from 9.30am through to 2.30pm.

Our confirmed Management for the event are listed below. Hikma Management will be spread out across 4 meeting rooms and investors & analysts will rotate rooms to meet everyone in 4 Q&A slots.

Corporate Focus:

Said Darwazah, Chairman & CEO

Bassam Kanaan, President and Chief Operating Officer for MENA and EU Region

Khalid Nabils, CFO

MENA Focus:

Mazen Darwazah, President & CEO MENA and Emerging Markets

Salah Mawajdah, Corporate Vice President Regulatory & Medical Affairs

Hassan Shafiq, Managing Director, Hikma Egypt

Basel Ziyadeh, General Manager / GCC

US Generics Focus:

Mike Raya, CEO West-Ward Pharmaceuticals

Brian Hoffman, VP Corporate Development West-Ward Pharmaceuticals

Fadi Nassar, Corporate VP API

Injectables Focus:

Riad Mishlawi, Vice President & Global Head of Injectables

Spiro Gavaris, VP Sales and Marketing West-Ward Pharmaceuticals

Natheer Masarweh, VP Quality Global Injectables and Operations (Portugal)

If you are interested in attending this event please contact Kate Komornicka kate@hikma.uk.com to register your interest and for further details.

-- ENDS --

Enquiries**Hikma Pharmaceuticals PLC**

Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/ +44 7776 477050

Lucinda Henderson, Deputy Head of Investor Relations +44 (0)20 7399 2765/ +44 7818 060211

FTI Consulting

Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Branded", "Injectables" and "Generics", based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of \$1,365 million and profit attributable to shareholders of \$212 million.